Lilly’s Intended Successor To Zyprexa Faces Uncertain Future After Phase III Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
Failure to perform better than placebo in the first of two pivotal Phase III trials diminishes chances of success for pomaglumetad methionil, a metabotropic glutamate 2/3 receptor agonist that Lilly hoped to position as a successor to its patent-expired schizophrenia therapy Zyprexa.